BerGenBio reports second quarter and half year 2022 financial results and provides business update
Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 BerGenBio to host conference call and webcast today at 10:00 AM CEST/4:00 AM EDT BERGEN, Norway, Aug. 23, 2022 /PRNewswire/ -- BerGenBio ASA (OSE:...
View More : https://www.prnewswire.com:443/news-releases/bergenbio-reports-second-quarter-and-half-year-2022-financial-results-and-p...
|